Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Love Lifesciences

Physician-led Kansas medtech developing UniPen, a universal vial-compatible self-injection pen aimed at cutting pharma device costs and lead times.

Overland Park, Kansas, United States, North AmericaMedTech & devices, Self-injection devicesKansas City 2026 (KCSourceLink; 10 finalists announced on 3 Sept. 2026, final on 22 Sept. 2026 at CPKC Stadium)
Stage
Pre-seedNo documented AI
Product
PrototypeFirst customers
Funding raised
$1.1Mdisclosed
Founded
20215 years ago
Founders
2Nick, Bradley
Global score
3.8Grade DRank 101 of 151

Overview

Love Lifesciences designs self-injection devices, including the UniPen, to make injections simpler for patients and reduce costs and lead times for pharmaceutical companies.

Traction

First customers

UniPen available through licensed pharmacies (not FDA-authorized); no pharma customer or partner named.

Market

Autoinjectors (devices)

Pharma companies select injection devices years before launch, increasingly for home self-administration of biologics and peptides. Custom autoinjectors are costly and slow to develop, so a universal pen compatible with standard vials could shorten timelines. Device choice is signed by pharma device/combination-product teams, and FDA combination-product rules govern market access. Incumbents (BD, Ypsomed) dominate.

Addressable market

2025
$4B
2030
$6.9B
+11.8% a year

Autoinjectors (devices): $3.95bn in 2025, +11.8%/year, $6.9bn in 2030 (Towards Healthcare).

Customers

Pharma and biotech companies with injectable drugs; compounding/specialty pharmacies; patients self-injecting

Who signs the cheque

Pharma device and combination-product teams; licensed pharmacies

Geographies

  • United States

Drivers

  • Shift of biologics and peptides to home self-administration
  • Pharma pressure to cut device development cost and time
  • Growth of chronic-disease injectables

Headwinds

  • No FDA authorisation yet
  • Entrenched incumbents (BD, Ypsomed)
  • Long pharma qualification cycles

The autoinjector (device) market is estimated at $3.95bn in 2025 (+11.8%/year, $12.1bn in 2035) according to Towards Healthcare; estimates that include drugs go well beyond this.

Scalability 5/10. Medical device that can be sold to pharmaceutical companies worldwide, but FDA/CE authorization and industrialization are required.

Market source: towardshealthcare.com

Technology

Category

Medical device – drug delivery

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

prototype

How it works

UniPen is a universal injector pen designed to work with standard vials for self-administration. This avoids drug-specific cartridges or prefilled syringes.

Moat

Weak until regulatory clearance and pharma contracts exist; potential IP on the universal vial interface.

Differentiation

Vial-compatible universal design vs drug-specific autoinjectors requiring custom primary containers.

Integration points

  • Pharma/biotech injectable pipelines
  • Specialty and compounding pharmacies
  • Medical-device contract manufacturers
  • Adherence/remote-monitoring platforms

Depends on

  • FDA clearance/combination-product pathway
  • Contract manufacturing at medical-grade quality
  • Pharma partnering

Use of AI

No use of AI mentioned

Product in detail

UniPen universal injector pen compatible with standard vials, for self-administration of drugs.

Business

Model
Device sales and/or licensing to pharma; currently available through licensed pharmacies.
Revenue logic
Per-device revenue plus potential platform licence per drug programme (not disclosed).
Go-to-market
Pharmacy availability today; target is pharma partnerships.

Next milestones

  1. FDA submission/clearance
  2. First pharma development agreement
  3. Contract-manufacturing scale-up

Key risks

  • Regulatory (FDA)
  • No pharma partner
  • Very limited capital

Opportunities

5 found in the network

Concrete moves for Love Lifesciences inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 2
  • Investors 2
  • Peers 1

Co-development2

An integration or joint product

Early device partnership for injectable nanobody formulations

Nanogrow develops nanobody biologics with an injectable route among others and is still preclinical, the phase when device choices are cheapest to make. Co-developing a vial-plus-UniPen presentation gives Love Lifesciences a first biologic programme and Nanogrow a low-cost self-administration option.

20%confidence

Evidence from the records

  • “Nanobody (sdAb) platform combined with local delivery formulations: topical, nebulized, injectable, oral or via DNA/RNA.”
  • “UniPen universal injector pen compatible with standard vials, for self-administration of drugs.”
If it works
A letter of intent naming UniPen as the candidate device for one programme, useful for both companies' fundraising.
First step
Share UniPen's viscosity/volume envelope with Nanogrow's formulation team.

Explore lower-cost manufacturing through Byonyks' Pakistan factory

Byonyks runs a regulator-approved device factory in Pakistan and has cleared a class II home-therapy device with the FDA. A contract-manufacturing or know-how arrangement could cut UniPen's unit cost and accelerate regulatory documentation; Byonyks fills factory capacity.

20%confidence

Evidence from the records

  • “DRAP-approved factory in Pakistan”
  • “FDA 510(k) clearance K243371 (decision of 16 May 2025, class II)”
  • “reduce costs and lead times for pharmaceutical companies”
If it works
A manufacturing quote and regulatory-pathway mentoring that de-risk the FDA plan.
First step
Ask Byonyks for its contract-manufacturing capabilities and ISO certification scope.

Investors2

A fund whose thesis fits

Pitch Robin Hood Ventures via Vytala Health

Robin Hood Ventures is a US angel network investing $0.25–0.5M at pre-seed/seed in HealthTech and life sciences, matching Love Lifesciences' stage. It led Vytala Health's round in the network, providing a warm introduction.

35%confidence

Evidence from the records

  • “Robin Hood Ventures (lead), Delaware Crossing Investment Group, Ulu Ventures, The MBA Fund, JumpStart NJ, business angel groups”
  • “~$1.2M (WIBW); $1.72M over 5 rounds according to CB Insights”
If it works
A seed cheque to fund the FDA pathway.
First step
Ask Vytala Health's founders for an introduction to Robin Hood Ventures' screening lead.

Use PharmStars' pharma network to land a first partner

PharmStars invests at pre-seed/seed in HealthTech and life sciences globally and is oriented to pharma partnerships, addressing Love Lifesciences' main gap (no pharma partner). It led Cromodata's round in the network.

30%confidence

Evidence from the records

  • “PharmStars Ventures (lead), Sancus Capital, Gabriela Pittis (business angel)”
  • “UniPen available through licensed pharmacies (not FDA-authorized); no pharma customer or partner named.”
If it works
Investment plus introductions to pharma device teams.
First step
Ask Cromodata's CEO for an intro to PharmStars and prepare a pharma-facing value proposition.

Peers1

Founders solving the same problem elsewhere

Share FDA and QMS learnings between two pre-clearance drug-delivery devices

Both companies are pre-FDA drug-delivery device makers founded by clinicians. Sharing regulatory consultants, QMS templates and test labs reduces cost for both.

25%confidence

Evidence from the records

  • “No public evidence of traction found: pump shown as a concept visual; funds intended for R&D, clinical validation and the FDA pathway.”
  • “High risk: regulatory (FDA), competition from BD/Ypsomed and little capital.”
If it works
Lower regulatory preparation costs through shared vendors.
First step
Set a call between the two founders to compare FDA pathway plans.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

US federal biomedical research agency funding biotech, health and medtech via SBIR and research grants (Defined Bioscience, Microvitality, Corticale).

US self-injection devices.

30%confidence

Evidence from the records

  • “MedTech & devices”
  • “Self-injection devices”
  • “UniPen available through licensed pharmacies (not FDA-authorized)”
Intro path
Founder-to-founder intro via Corticale, Defined Bioscience, Microvitality (network portfolio company of U.S. National Institutes of Health (NIH)).
First step
Apply SBIR.

US accelerator with no public profile in our data; supported maternal-health medtech Lidavex.

US pre-seed self-injection devices — early medtech.

25%confidence

Evidence from the records

  • “Lidavex”
  • “Self-injection devices”
  • “UniPen available through licensed pharmacies (not FDA-authorized)”
Intro path
Founder-to-founder intro via Lidavex (network portfolio company of Gust Accelerator).
First step
Ask Lidavex for programme details.

US accelerator with no profile in our data; supported maternal-health medtech Lidavex.

US self-injection devices.

25%confidence

Evidence from the records

  • “Lidavex”
  • “Self-injection devices”
  • “UniPen available through licensed pharmacies (not FDA-authorized)”
Intro path
Founder-to-founder intro via Lidavex (network portfolio company of Octane LaunchPad).
First step
Low priority.

US angel network investing at pre-seed and seed; backed Vytala Health's $805K pre-seed in medical nutrition.

US pre-seed self-injection devices — angel-stage medtech.

25%confidence

Evidence from the records

  • “Vytala Health”
  • “Self-injection devices”
  • “UniPen available through licensed pharmacies (not FDA-authorized)”
Intro path
Founder-to-founder intro via Vytala Health (network portfolio company of JumpStart NJ Angel Network).
First step
Check NJ presence first.

Investment analysis

3.8D

Grade D

Rank 101 of 151

Disruption4.0/10
Business model3.0/10
Market4.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early and too exposed to regulatory risk.

Disruption

4/10

UniPen self-injection device: incremental improvement in a known category.

Business model

3/10

Available through pharmacies, not FDA-authorized, no pharma partner named.

Market

4/10

TAM $3.95bn → base 4; scalability 5/10 (neutral); no international presence: no partner named → 4/10.

Risk

7/10

Lower is better

High risk: regulatory (FDA), competition from BD/Ypsomed and little capital.

Strengths

  • Physician founder
  • Growing self-injection market

Risks

  • No FDA authorization
  • No pharma partner

Funding

$1.1M, disclosed
  1. 2022

    crowdfunding$124K

    Wefunder

  2. 2022-2023

    grants/prizesnot specified

    Digital Sandbox KC, Kansas Department of Commerce

  3. 2023-07

    pre-seed$1M ($600K raised + $400K committed)

    Kansas business angels, GROWKS

  4. 2026-02-05

    grant (proof-of-concept)$25K

    ACCEL-KS (KU Innovation Park)

Amount used in the study. $124K crowdfunding + $1M pre-seed (of which $400K committed) + $25K grant; $1.72M CB Insights as upper bound.

Note. ~$1.2M (WIBW, 2023); $1.72M over 5 rounds (CB Insights)

Selection for the Kansas City 2026 regional confirmed (Startland News); new $25K ACCEL-KS grant (Feb. 2026). Website: UNIPEN® single-use pre-dosed pen, not FDA-authorized with compounded drugs; ~50% of patients choose it when offered (self-reported).

Team

  • Nick Love

    Co-founder & CEO

    Physician (MD) and MBA, biopharma business/research analyst; BioKansas board member.

  • Bradley Hopper

    Co-founder & CTO

    More than 10 years founding companies, in product design and engineering.

Sources

Regional final
Kansas City 2026 (KCSourceLink; 10 finalists announced on 3 Sept. 2026, final on 22 Sept. 2026 at CPKC Stadium)
Identification confidence
high
  1. 1wibw.com/2023/07/20/kansas-startup-raises-1-million-expansion-produc
  2. 2cbinsights.com/company/love-lifesciences
  3. 3wefunder.com/lovelifesciences/
  4. 4startlandnews.com/2026/09/startup-world-cup-kansas-city-2/
  5. 5startlandnews.com/2026/02/accel-ks-ku-innovation-park/
  6. 6lovelifesciences.com/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet